BLIS Technologies (NZSE:BLT) Equity-to-Asset : 0.89 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BLIS Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NZ$11.49 Mil. BLIS Technologies's Total Assets for the quarter that ended in Mar. 2024 was NZ$12.93 Mil. Therefore, BLIS Technologies's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.89.

The historical rank and industry rank for BLIS Technologies's Equity-to-Asset or its related term are showing as below:

NZSE:BLT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.66 Med: 0.83 Max: 0.92
Current: 0.89

During the past 13 years, the highest Equity to Asset Ratio of BLIS Technologies was 0.92. The lowest was 0.66. And the median was 0.83.

NZSE:BLT's Equity-to-Asset is ranked better than
83.37% of 1539 companies
in the Biotechnology industry
Industry Median: 0.66 vs NZSE:BLT: 0.89

BLIS Technologies Equity-to-Asset Historical Data

The historical data trend for BLIS Technologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Equity-to-Asset Chart

BLIS Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Equity-to-Asset

Get a 7-Day Free Trial

0.72

0.73

0.86

0.85

0.89

BLIS Technologies Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial															0.86	0.84	0.85	0.85	0.89

Competitive Comparison of BLIS Technologies's Equity-to-Asset

For the Biotechnology subindustry, BLIS Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLIS Technologies's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Equity-to-Asset falls into.

BLIS Technologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BLIS Technologies's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	11.488	/	12.933
	=	0.89

BLIS Technologies's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	11.488	/	12.933
	=	0.89

BLIS Technologies (NZSE:BLT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

BLIS Technologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BLIS Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016

Website

https://www.blis.co.nz

BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).